| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-11-14 | ONS-3010 (biosimilar version of Humira® (adalimumab)) | 1 | Oncobiologics (USA - NJ) | Autoimmune diseases | |
| 2016-11-14 | sacituzumab govitecan - IMMU-132 | epithelial cancers including triple-negative breast cancer, non-small cell lung cancer, small-cell lung cancer | 2 | Immunomedics (USA - NJ) | Cancer - Oncology |
| 2016-11-13 | inclisiran (ALN-PCSsc) | hypercholesterolemia | 1 | Alnylam Pharmaceuticals (USA - MA) The Medicines Company (USA - NJ) | Cardiovascular diseases - Metabolic diseases |
| 2016-11-12 | romosozumab (CDP7851/AMG 785) | osteoporosis in men | 3 | Amgen (USA - CA) UCB (Belgium) | Bone diseases |
| 2016-11-11 | dabigatran etexilate | non-valvular atrial fibrillation | 3 | Boehringer Ingelheim (Germany) | Cardiovascular diseases |
| 2016-11-11 | aldoxorubicin | soft tissue sarcoma | 1b-2 | CytRx Corporation (USA - CA) | Cancer - Oncology |
| 2016-11-11 | migalastat | Fabry disease | 3 | Amicus Therapeutics (USA - NJ) | Rare diseases - Genetic diseases |
| 2016-11-11 | sebelipase alfa | lysosomal acid lipase deficiency (LAL Deficiency) | 3 | Synageva BioPharma (USA - MA), now Alexion Pharmaceuticals (USA - CT) | Rare diseases |
| 2016-11-10 | blisibimod | systemic lupus erythematosus (SLE) | 3 | Anthera Pharmaceuticals (USA - CA) | Autoimmune diseases |
| 2016-11-10 | custirsen | non-small cell lung cancer (NSCLC) | 3 | OncoGenex Pharmaceuticals (USA - WA) | Cancer - Oncology |
| 2016-11-10 | custirsen (OGX-011) | prostate cancer | 3 | OncoGenex Pharmaceuticals (USA - WA) | Cancer - Oncology |
| 2016-11-10 | GLS-5700 | Zika virus infection | preclinical | Inovio Pharmaceuticals (USA - PA) | Infectious diseases |
| 2016-11-10 | daratumumab, carfilzomib and dexamethasone | patients with multiple myeloma who have received one to three prior therapies | 3 | Amgen (USA - CA) Janssen Biotech, a J&J company (USA - NJ) | Cancer - Oncology |
| 2016-11-09 | ARC-520 | hepatitis B | 2 | Arrowhead Pharmaceuticals (USA - CA) | Infectious diseases |
| 2016-11-09 | CA-170 | advanced solid tumors, lymphoma | 1 | Curis (USA - MA) | Cancer - Oncology |
| 2016-11-08 | Adcetris® (brentuximab vedotin) | CD30-positive mature T-cell lymphoma (MTCL) | 3 | Millenium Pharmaceuticals (USA - MA) Seattle Genetics (USA - WA), wholly owned subsidiaries of Takeda Pharmaceutical (Japan) | Cancer - Oncology |
| 2016-11-08 | mRNA-encoded antibodies, RNAntibody® technology. | preclinical | Curevac (Germany) | ||
| 2016-11-08 | Viaskin® Milk | cow milk allergy | 2 | DBV Technologies (France) | Allergic diseases |
| 2016-11-07 | macitentan | chronic thromboembolic pulmonary hypertension | 2 | Actelion (Switzerland) | Rare diseases - Cardiovascular diseases - Respiratory diseases |
| 2016-11-07 | IFN alpha-Kinoid | systemic lupus erythematosus | 2b | Neovacs (France) | Autoimmune diseases - Dermatological diseases - Inflammatory diseases |
